{"id":"W2002937040","doi":"10.1371/journal.pmed.0020073","title":"Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain","year":2005,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3526,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Washington University in St. Louis; Genentech; AstraZeneca; LUNGevity Foundation; Memorial Sloan-Kettering Cancer Center; CHEST Foundation; Canadian Institutes of Health Research; American Cancer Society","keywords":"Gefitinib; Erlotinib; T790M; Cancer research; Epidermal growth factor receptor; Lung cancer; Resistance mutation; Medicine; Mutation; Erlotinib Hydrochloride; Tyrosine kinase; Tyrosine-kinase inhibitor; Biology; Cancer; Oncology; Internal medicine; Genetics; Receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}